NEW YORK – Tempus on Monday announced a strategic collaboration with Janssen Research & Development in oncology clinical development programs and data science.
For this collaboration, Tempus said that it is developing a predictive machine-learning model to improve enrollment in biomarker-driven clinical trials for Janssen R&D, a unit of Johnson & Johnson's Janssen Pharmaceutica. According to Chicago-based Tempus, Janssen is looking for a method to speed up the identification of patients with specific tumor features that match the requirements of trials.
The companies also said that Janssen has joined Tempus' TIME Trial network to accelerate patient enrollment in oncology clinical trials.
The Tempus Integrated Molecular Evaluation (TIME) Trial program features a proprietary technology platform that analyzes molecular and clinical data on cancer patients in real time to find suitable and convenient trials for individuals. Tempus said that organizations participating in TIME Trial can have patients enrolled in research within 10 days of bringing a biomarker-targeted trial online.
Several Janssen oncology trials are already taking advantage of TIME Trial, according to Tempus.
"Janssen is the ideal collaborator for this kind of forward-thinking collaboration, in which both companies utilize their respective strengths to improve patient care," Tempus COO Ryan Fukushima said in a statement. "We are harnessing the power of AI and data to deliver patients more personalized therapeutics faster."
Janssen is the second major pharma company to join TIME Trial recently. Laboratory Corporation of America's Covance drug development subsidiary did so in September.